ARGXargenx SE

$46B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$411M-17.4% YoY

Gross Profit

$381M92.8% margin

Operating Income

-$720M-175.4% margin

Net Income

-$710M-172.8% margin

EPS (Diluted)

$-13.05

Cash Flow

Operating Cash Flow

-$863M

Free Cash Flow

-$967M

Stock-Based Comp.

$157M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$321M

Stockholders' Equity

$2.8B

Cash & Equivalents

$801M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$411M	$497M	-17.4%
Gross Profit	$381M	$497M	-23.3%
Operating Income	-$720M	-$349M	-106.6%
Net Income	-$710M	-$408M	-74.1%

ARGX FY 2022 Earnings — argenx SE Revenue & Financial Results | Market Cap Arena